The science and engineering behind continuous manufacturing (CM) has demonstrated the advantages this advanced technology has over tried and true batch manufacturing for pharmaceutical drug production. Nevertheless, adoption of CM has proceeded more slowly despite FDA support and reported benefits from various pilots and use cases. Part of what holds back further expansion of CM is uncertainty associated with capital and operating costs as well as touted efficiencies in the CM process. Making the case to senior management for CM, including financial decision makers requires an approach that takes a page from other industries to better make decisions under uncertainty with greater confidence. We’ll show how to turn your CM investment decision into a distribution of net present values (NPVs) in a simulation-based methodology that allows decision makers to invest in CM projects with greater levels of confidence.
